Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Emeritus Professor Philip Home.

Newcastle AuthorsTitleYearFull text
Emeritus Professor Philip Home
Insulin therapy development beyond 100 years2022
Emeritus Professor Philip Home
Can we find out if COVID-19 causes diabetes?2021
Emeritus Professor Philip Home
Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison2021
Emeritus Professor Philip Home
Future directions in insulin therapy2021
Emeritus Professor Philip Home
Heart failure management; a perspective from diabetes care2021
Emeritus Professor Philip Home
Lingering effects of hyperglycemia in recently diagnosed diabetes during long-term follow-up of the dcct/edic and ukpds cohorts: More evidence that early control matters2021
Emeritus Professor Philip Home
Tackling obesity during the COVID-19 pandemic2021
Emeritus Professor Philip Home
The evolution of insulin therapy2021
Emeritus Professor Philip Home
Comparison of multiple cut points for time in range in relation to risk of abnormal carotid intima-media thickness and diabetic retinopathy2020
Emeritus Professor Philip Home
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison.2020
Emeritus Professor Philip Home
How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?2020
Emeritus Professor Philip Home
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial2020
Emeritus Professor Philip Home
Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: A randomized trial2020
Emeritus Professor Philip Home
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis2020
Emeritus Professor Philip Home
Is Insulin Therapy Safe?2020
Emeritus Professor Philip Home
Cardiovascular outcome trials of glucose-lowering medications: an update2019
Emeritus Professor Philip Home
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%2019
Emeritus Professor Philip Home
Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground2019
Emeritus Professor Philip Home
Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program2019
Emeritus Professor Philip Home
The Need for Accuracy in Hemoglobin A1c Proficiency Testing: Why the Proposed CLIA Rule of 2019 Is a Step Backward2019
Emeritus Professor Philip Home
2020 vision – An overview of prospects for diabetes management and prevention in the next decade2018
Emeritus Professor Philip Home
A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes2018
Emeritus Professor Philip Home
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes2018
Emeritus Professor Philip Home
Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events2018
Emeritus Professor Philip Home
Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study2018
Emeritus Professor Philip Home
Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. Diabetes Care 2017;40:655–6622018
Emeritus Professor Philip Home
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial2018
Emeritus Professor Philip Home
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial2018
Emeritus Professor Philip Home
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)2018
Emeritus Professor Philip Home
Need for regulatory change to incorporate beyond A1C glycemic metrics2018
Emeritus Professor Philip Home
A diabetes mellitus guideline gone wrong - the 2017 ACP update2017
Emeritus Professor Philip Home
Comment on Abd El Aziz et al., A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients2017
Emeritus Professor Philip Home
Comment on Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems 2005–2011. Diabetes Care 2016: 39; 363–3702017
Emeritus Professor Philip Home
Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial2017
Emeritus Professor Philip Home
Incorporating Site-Less Clinical Trials Into Drug Development: A Framework for Action2017
Emeritus Professor Philip Home
Insulin regimens and glycemic control in different parts of Europe over 4 years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study2017
Emeritus Professor Philip Home
Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting2017
Emeritus Professor Philip Home
Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy2017
Emeritus Professor Philip Home
A clinically defined nocturnal window for analysis of hypoglycemia: New insulin glargine 300U/ML (GLA-300) in type 2 diabetes (T2DM)2016
Emeritus Professor Philip Home
Clinical use of the co-formulation of insulin degludec and insulin aspart2016
Emeritus Professor Philip Home
Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes2016
Emeritus Professor Philip Home
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?2016
Emeritus Professor Philip Home
IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status2016
Emeritus Professor Philip Home
Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin2016
Emeritus Professor Philip Home
A common fallacy of observational medication studies in diabetes2015
Emeritus Professor Philip Home
Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum2015
Emeritus Professor Philip Home
Albiglutide provides effective glycaemic lowering across diabetes duration subgroups2015
Emeritus Professor Philip Home
An analysis of the cost-effectiveness of starting insulin detemir in insulin-naive people with type 2 diabetes2015
Emeritus Professor Philip Home
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins2015
Emeritus Professor Philip Home
Biosimilar insulins: guidance for data interpretation by clinicians and users2015
Emeritus Professor Philip Home
Cancer and bone fractures in observational follow-up of the RECORD study2015
Emeritus Professor Philip Home
Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research2015
Dr Augustin Brooks
Emeritus Professor Philip Home
Dr Nick Steen
Professor James Shaw
Demonstration of an Intrinsic Relationship Between Endogenous C-Peptide Concentration and Determinants of Glycemic Control in Type 1 Diabetes Following Islet Transplantation2015
Emeritus Professor Philip Home
Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 52015
Emeritus Professor Philip Home
Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents2015
Emeritus Professor Philip Home
Glycemic Control and Hypogycemia with New Insulin Glargine 300 U/ML in People with Type 1 Diabetes (Edition 4)2015
Emeritus Professor Philip Home
Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes2015
Emeritus Professor Philip Home
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)2015
Emeritus Professor Philip Home
New Insulin Glargine 300 U/ML: Efficacy and Safety of Flexible vs Fixed Dosing Intervals in People with Type 2 Diabetes Mellitus2015
Emeritus Professor Philip Home
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)2015
Emeritus Professor Philip Home
New insulin glargine 300U/ml (Gla-300): glycaemic control and hypoglycaemia in insulin-naive people with Type 2 diabetes compared with glargine 100U/ml (Gla-100)2015
Emeritus Professor Philip Home
New insulin glargine 300U/ml in people with Type 2 diabetes using basal insulin plus oral glucose lowering drugs compared with glargine 100U/ml (EDITION 2): less nocturnal hypoglycaemia and weight gain2015
Emeritus Professor Philip Home
New insulin glargine 300U/ml in Type 2 diabetes using basal plus meal-time insulin: sustained glycaemic control and less hypoglycaemia compared with glargine 100U/ml (EDITION 1)2015
Emeritus Professor Philip Home
One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension2015
Emeritus Professor Philip Home
Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose?2015
Emeritus Professor Philip Home
Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?2015
Emeritus Professor Philip Home
Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study2015
Emeritus Professor Philip Home
Sustained Glycemic Control and Less Hypoglycemia with New Insulin Glargine 300 U/ML: 1-Year Results in T2DM with Basal plus Mealtime Insulin (Edition 1)2015
Emeritus Professor Philip Home
An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naive people with poorly controlled type 2 diabetes2014
Emeritus Professor Philip Home
Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management Reflections From a Diabetes Care Editors' Expert Forum2014
Emeritus Professor Philip Home
Cardiovascular outcomes and their relationship to risk factors and baseline disease over 4 years when starting insulin in type 2 diabetes: the CREDIT study2014
Emeritus Professor Philip Home
Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin2014
Emeritus Professor Philip Home
Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin. Diabetes Care 2014;37:2108-21132014
Emeritus Professor Philip Home
Four-year analysis of insulin dose and hypoglycaemia in the real-world treatment of type 2 diabetes: results from the CREDIT study2014
Emeritus Professor Philip Home
Glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL in people with type 1 diabetes (EDITION 4)2014
Emeritus Professor Philip Home
Harmony 5-year 3 Results: albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in people with type 2 diabetes2014
Emeritus Professor Philip Home
Hypoglycaemia in people with type 2 diabetes achieving vs not achieving HbA1c target levels over 4 years in routine clinical practice: analysis of the CREDIT study2014
Emeritus Professor Philip Home
Impact of biosimilar insulins on clinical practice: Meeting report2014
Emeritus Professor Philip Home
Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?2014
Emeritus Professor Philip Home
Investigational new insulin glargine U300: glucose control and hypoglycaemia in people with Type 2 diabetes using a basal plus mealtime insulin regimen (EDITION I)2014
Emeritus Professor Philip Home
Neues Insulin glargin U300: Blutzuckerkontrolle undHypoglykämiehäufigkeit bei Patienten mit Typ-2-Diabetes und einem Therapieschema aus Basal- undMahlzeiteninsulin (EDITION I) [New Insulin glargin U300: Blood Sugar Control and Hypoglycemic Frequency for Patients with Type-2-Diabetes and a Treatment Scheme from Basal- and Meal Insulin (EDITION I)]2014
Emeritus Professor Philip Home
New insulin glargine 300 U/ml: efficacy and safety of flexible vs fixed dosing intervals in people with type 2 diabetes mellitus2014
Emeritus Professor Philip Home
New insulin glargine 300 U/ml: glycaemic control and hypoglycaemia in insulin-naive people with type 2 diabetes mellitus (EDITION 3)2014
Emeritus Professor Philip Home
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)2014
Emeritus Professor Philip Home
People with type 2 diabetes with lower HbA1c using insulin experience fewer cardiovascular events and death: results from the CREDIT study2014
Emeritus Professor Philip Home
Predictive and Explanatory Factors of Change in HbA1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs2014
Emeritus Professor Philip Home
Relationship of HbA1c with body weight change over 4 years from starting insulin therapy in people with type 2 diabetes: the CREDIT study2014
Emeritus Professor Philip Home
Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014; 37: 1499-15082014
Emeritus Professor Philip Home
RESPONSE TO COMMENT ON HOME ET AL. Predictive and Explanatory Factors of Change in HbA(1c) in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs. Diabetes Care 2014;37:1237-12452014
Emeritus Professor Philip Home
Safety, Tolerability, and Efficacy of Insulin Aspart in People with Type 2 Diabetes, as Biphasic Insulin Aspart or with Basal Insulin: Findings from the Multinational, Non-Interventional A1chieve Study2014
Emeritus Professor Philip Home
The vexed question of hypoglycaemia and health economics2014
Emeritus Professor Philip Home
52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with type 2 diabetes: HARMONY 5 study2013
Emeritus Professor Philip Home
A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes2013
Emeritus Professor Philip Home
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)2013
Emeritus Professor Philip Home
Biphasic Insulin Aspart 30 in Insulin-Naive People with Type 2 Diabetes in Non-western Nations: Results from a Regional Comparative Multinational Observational Study (A1chieve)2013
Emeritus Professor Philip Home
Comparison of National/Regional Diabetes Guidelines for the Management of Blood Glucose Control in non-Western Countries2013
Emeritus Professor Philip Home
Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents2013
Emeritus Professor Philip Home
Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes2013
Emeritus Professor Philip Home
Insulin Therapy and Cancer2013
Emeritus Professor Philip Home
Methodology of a re-evaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct2013
Emeritus Professor Philip Home
New Insulin Glargine Formulation: Glucose Control and Hypoglycaemia in People with Type 2 Diabetes Using Basal and Mealtime Insulin (EDITION I)2013
Emeritus Professor Philip Home
Observational research: an integral part of enhancing diabetes management in south-east Asia2013
Emeritus Professor Philip Home
Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum2013
Emeritus Professor Philip Home
Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK2013
Emeritus Professor Philip Home
Results of a re-evaluation of cardiovascular outcomes in the RECORD trial2013
Emeritus Professor Philip Home
The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-Western nations: Results from the A1chieve observational study2013
Emeritus Professor Philip Home
Validity of Meta-analysis in Diabetes: We Need to Be Aware of Its Limitations2013
Emeritus Professor Philip Home
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials2012
Emeritus Professor Philip Home
Cardiovascular Disease and Oral Agent Glucose-Lowering Therapies in the Management of Type 2 Diabetes2012
Emeritus Professor Philip Home
Diabetes complications and BMI in Asia, Africa, Europe, and Latin America: A1chieve baseline data2012
Emeritus Professor Philip Home
Diabetes therapy and prevention of vascular damage2012
Emeritus Professor Philip Home
Erratum to: Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials2012
Emeritus Professor Philip Home
Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes2012
Emeritus Professor Philip Home
Global guideline for type 2 diabetes2012
Emeritus Professor Philip Home
Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes2012
Emeritus Professor Philip Home
Improving health outcomes in 2011 for people with type 2 diabetes: a report from a symposium held on the occasion of the International Diabetes Federation World Diabetes Congress, Dubai, 5-8 December 20112012
Emeritus Professor Philip Home
Macrovascular and microvascular outcomes after beginning of insulin versus additional oral glucose-lowering therapy in people with type 2 diabetes: an observational study2012
Emeritus Professor Philip Home
Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy2012
Emeritus Professor Philip Home
Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease2012
Emeritus Professor Philip Home
Profiles of cardiovascular risk in people with type 2 diabetes: baseline data from a1chieve study2012
Emeritus Professor Philip Home
The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences2012
Emeritus Professor Philip Home
A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes2011
Emeritus Professor Philip Home
A comparison of quality of life measured with the SF-36 for insulin degludec and insulin glargine in people with type 1 diabetes2011
Emeritus Professor Philip Home
A meta-analysis of maternal outcomes in pregnant women using insulin glargine compared with NPH insulin2011
Emeritus Professor Philip Home
An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-western countries: The A1chieve study2011
Emeritus Professor Philip Home
Biosimilar insulins2011
Dr Latika Sibal
Dr Sharad Agarwal
Emeritus Professor Philip Home
Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes2011
Emeritus Professor Philip Home
Factors associated with weight gain in type 2 diabetic patients starting on insulin: the CREDIT study2011
Dr Stuart Little
Professor James Shaw
Emeritus Professor Philip Home
Hypoglycemic rates with basal insulin analogs2011
Emeritus Professor Philip Home
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes : a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in diabetes (RECORD) study2011
Emeritus Professor Philip Home
Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study2011
Emeritus Professor Philip Home
Insulin Degludec in Type 1 Diabetes A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine2011
Emeritus Professor Philip Home
Quality standard for diabetes in adults2011
Emeritus Professor Philip Home
Safety of PPAR agonists2011
Emeritus Professor Philip Home
Should A1C targets be individualized for all people with diabetes? Arguments for and against2011
Emeritus Professor Philip Home
Structured care for diabetes should cover a spectrum of areas2011
Emeritus Professor Philip Home
A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study2010
Emeritus Professor Philip Home
Duration of first insulin therapy in previously uncontrolled type 2 diabetes: Comparison of insulins glargine, detemir and NPH and association with glycemic control [abstract]2010
Dr Shaikh Abdul Shakoor
Dr Ali Aldibbiat
Lorna Ingoe
Dr Susan Campbell
Dr Latika Sibal
et al.
Endothelial Progenitor Cells in Subclinical Hypothyroidism: The Effect of Thyroid Hormone Replacement Therapy2010
Emeritus Professor Philip Home
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials2010
Dr Latika Sibal
Dr R Neely
Emeritus Professor Philip Home
Friedewald equation underestimates low-density lipoprotein cholesterol at low concentrations in young people with and without Type 1 diabetes2010
Emeritus Professor Philip Home
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial2010
Emeritus Professor Philip Home
How can observational trials inform and improve clinical practice?2010
Emeritus Professor Philip Home
Insufficient evaluation of adverse events is not a proof of safety. Reply to LG Hemkens, U Grouven, R Bender, et al. [letter]2010
Dr Latika Sibal
Crispian Oates
Emeritus Professor Philip Home
Lipoprotein associations with endothelial dysfunction and carotid intima-media thickness in young people with Type 1 diabetes2010
Emeritus Professor Philip Home
Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance2010
Emeritus Professor Philip Home
Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine2010
Emeritus Professor Philip Home
Observational studies: Going beyond the boundaries of randomized controlled trials2010
Dr Reena Thomas
Emeritus Professor Philip Home
Recommended management of type 1 diabetes with insulin2010
Emeritus Professor Philip Home
Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: A pooled analysis of treat-to-target trials2010
Dr Latika Sibal
Dr Sharad Agarwal
Emeritus Professor Philip Home
The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease2010
Dr Latika Sibal
Emeritus Professor Philip Home
A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria2009
Dr Umesh Dashora
Dr Simon Ashwell
Emeritus Professor Philip Home
An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes2009
Dr Latika Sibal
Dr Ali Aldibbiat
Dr Sharad Agarwal
Crispian Oates
Dr Salman Razvi
et al.
Circulating endothelial progenitor cells, endothelial function, carotid intima-media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria2009
Emeritus Professor Philip Home
Combined randomised controlled trial experience of malignancies in studies using insulin glargine2009
Emeritus Professor Philip Home
Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes: A randomized open parallel multicenter study2009
Emeritus Professor Philip Home
Estimating number-needed-to-treat with insulin glargine compared with NPH insulin to avoid a hypoglycaemic episode in people with type 2 diabetes mellitus: a meta-analysis2009
Dr Latika Sibal
Emeritus Professor Philip Home
Management of type 2 diabetes: NICE guidelines2009
Emeritus Professor Philip Home
Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins2009
Emeritus Professor Philip Home
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial2009
Emeritus Professor Philip Home
Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes2009
Emeritus Professor Philip Home
Surgery and the prevention of limb loss in diabetes2009
Emeritus Professor Philip Home
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes2008
Peter Curtis
Emeritus Professor Philip Home
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)2008
Emeritus Professor Philip Home
HbA1c: The case for using estimated average glucose (eAG)2008
Emeritus Professor Philip Home
Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: A critical target for insulin-sensitizing agents2008
Emeritus Professor Philip Home
Impact of the UKPDS - An overview2008
Emeritus Professor Philip Home
Injection site abscesses2008
Dr Latika Sibal
Dr Ali Aldibbiat
Crispian Oates
Dr Jolanta Weaver
Professor James Shaw
et al.
The influence of the presence of retinopathy on the circulating endothelial progenitor cell counts, endothelial function and carotid intima-media thickness in type I diabetes2008
Dr Simon Ashwell
Emeritus Professor Philip Home
Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes2008
Emeritus Professor Philip Home
A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with type 2 diabetes2007
Emeritus Professor Philip Home
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK2007
Emeritus Professor Philip Home
Change in plasma glucose following exercise in type 1 diabetes: a comparison of three basal insulins2007
Emeritus Professor Philip Home
Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia 50:259-267 [2]2007
Dr Latika Sibal
Emeritus Professor Philip Home
Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): Good for sulfonylureas?2007
Dr Ebaa Al-Ozairi
Emeritus Professor Philip Home
Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): Good for Sulfonylureas?2007
Emeritus Professor Philip Home
Early retinopathy progression in four randomized trials comparing insulin glargine and Nph insulin2007
Dr Latika Sibal
Dr Ali Aldibbiat
Dr Jolanta Weaver
Dr Salman Razvi
Crispian Oates
et al.
Endothelial dysfunction and circulating endothelial progenitor cells in young people with type 1 diabetes2007
Dr Latika Sibal
Dr Ali Aldibbiat
Dr Sharad Agarwal
Dr Jolanta Weaver
Dr Salman Razvi
et al.
Endothelial dysfunction, carotid intima media thickness and circulating endothelial progenitor cells in young people with Type 1 diabetes2007
Dr Umesh Dashora
Dr Latika Sibal
Dr Simon Ashwell
Emeritus Professor Philip Home
Insulin glargine in combination with nateglinide in people with Type 2 diabetes: A randomized placebo-controlled trial2007
Emeritus Professor Nick Europe-Finner
Emeritus Professor John Gibson
Emeritus Professor Philip Home
Professor David Leaper
Professor Roy Taylor
et al.
Medical training in the UK: sleepwalking to disaster2007
Emeritus Professor Philip Home
Professor David Leaper
Professor Roy Taylor
Modernising Medical Careers, Medical Training Application Service, and the Postgraduate Medical Education and Training Board: time for the emperors to don their clothes2007
Dr Latika Sibal
Janice Gebbie
Emeritus Professor Philip Home
Risk factors for incidence and progression of diabetic retinopathy in people with Type 1 diabetes: a 9-year follow-up study2007
Emeritus Professor Philip Home
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis2007
Emeritus Professor Philip Home
Peter Curtis
Rosiglitazone RECORD study: Glucose control outcomes at 18 months2007
Dr Tim Butler
Emeritus Professor Philip Home
The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes2007
Dr Latika Sibal
Dr Ali Aldibbiat
Ian Harvey
Dr Brian Shenton
Dr Graham Holliman
et al.
[abstract] Identification and quantification of circulating endothelial progenitor cells in individuals with Type 1 diabetes and non-diabetic controls2006
Emeritus Professor Philip Home
Peter Curtis
[abstract] Prolonged efficacity on 12 months of rosiglitazone given in association on ambulatory arterial stiffness in patients suffering type 2 diabetes2006
Emeritus Professor Philip Home
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-Naïve people with type 2 diabetes2006
Emeritus Professor Philip Home
A digest of the Global Guideline for Type 2 Diabetes.2006
Emeritus Professor Philip Home
A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies2006
Dr Latika Sibal
Janice Gebbie
Emeritus Professor Philip Home
Cardiovascular risk factors predicting the development of distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up study2006
Emeritus Professor Philip Home
Cost-effectiveness of CSII2006
Emeritus Professor Philip Home
Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia2006
Emeritus Professor Philip Home
Global Guideline for Type 2 Diabetes: Recommendations for standard, comprehensive, and minimal care2006
Emeritus Professor Philip Home
Identifying the impact of diabetes research2006
Dr Simon Ashwell
Professor Rudy Bilous
Dr Umesh Dashora
Emeritus Professor Philip Home
Improved glycaemic control with insulin glargine plus insulin lispro: A multicentre, randomized, cross-over trial in people with Type 1 diabetes2006
Emeritus Professor Philip Home
Insulin detemir: From concept to clinical experience2006
Emeritus Professor Philip Home
Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes - Reply2006
Dr Simon Ashwell
Janice Gebbie
Emeritus Professor Philip Home
Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times2006
Dr Latika Sibal
Janice Gebbie
Dr Umesh Dashora
Dr Sharad Agarwal
Emeritus Professor Philip Home
et al.
Predicting the development of macrovascular disease in people with type 1 diabetes: A 9-year follow-up study2006
Emeritus Professor Philip Home
Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes2006
Emeritus Professor Philip Home
The authors' reply2006
Emeritus Professor Philip Home
The diabetes epidemic and the developing world2006
Emeritus Professor Philip Home
Time of evening administration of insulin detemir can be fitted to individual needs and lifestyle2006
Dr Simon Ashwell
Janice Gebbie
Emeritus Professor Philip Home
Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart2006
Emeritus Professor Philip Home
A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes2005
Emeritus Professor Philip Home
Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes2005
Emeritus Professor Philip Home
Global Guideline for Type 2 Diabetes2005
Emeritus Professor Philip Home
Guidelines for the treatment and management of new-onset diabetes after transplantation2005
Dr Robert Thomas
Emeritus Professor Philip Home
Insulin therapy for people with Type 1 diabetes2005
Peter Curtis
Emeritus Professor Philip Home
Randomized controlled trial of the effect of rosiglitazone in combination therapy on ambulatory blood pressure in people with type 2 diabetes mellitus followed for 12 months2005
Peter Curtis
Emeritus Professor Philip Home
Rosiglitazone combination therapy lowers ambulatory blood pressure (ABP) over a twelve month period in patients with Type 2 diabetes mellitus2005
Emeritus Professor Philip Home
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol2005
Emeritus Professor Philip Home
The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes2005
Dr Simon Ashwell
Janice Gebbie
Emeritus Professor Philip Home
Comparison of insulin glargine injection at lunchtime, dinner-time and bedtime in people with Type 1 diabetes using mealtime insulin lispro2004
Emeritus Professor Philip Home
Death from diabetes2004
Emeritus Professor Philip Home
Diabetes Care in need2004
Emeritus Professor Philip Home
Efficacy, insulin dose and antibody formation in a four-year trial comparing twice daily biphasic insulin aspart 30 with twice daily biphasic human insulin2004
Emeritus Professor Philip Home
Glucose: sweetness and toxin2004
Emeritus Professor Philip Home
Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: An evidence-based strategy to reduce the burden of late-developing diabetes complications2004
Emeritus Professor Philip Home
Insulin Detemir Offers Improved Glycemic Control Compared with NPH Insulin in People with Type 1 Diabetes: A randomized clinical trial2004
Emeritus Professor Philip Home
It's all about the people2004
Emeritus Professor Philip Home
Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes2004
Emeritus Professor Philip Home
Not the blank slate2004
Emeritus Professor Philip Home
Prevention and management of foot problems in Type 2 diabetes. Also summarized as NICE guideline2004
Emeritus Professor Philip Home
Principles for national and regional guidelines on cardiovascular disease prevention - A scientific statement from the World Heart and Stroke Forum2004
Emeritus Professor Philip Home
Peter Curtis
Rosiglitazone combination therapy improves ambulatory blood pressure: A 6-month substudy of the RECORD trial in people with type 2 diabetes2004
Emeritus Professor Philip Home
Standardisation of glycated haemoglobin2004
Emeritus Professor Philip Home
Standardisation of glycated haemoglobin [Editorial]2004
Emeritus Professor Philip Home
Understanding the evidence2004
Emeritus Professor Philip Home
A diabetes presence2003
Emeritus Professor Philip Home
A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes2003
Emeritus Professor Philip Home
Diabetes beyond health care2003
Emeritus Professor Philip Home
Going down: lipids and all that cholesterol2003
Emeritus Professor Philip Home
Dr Peter Senior
Hypertension in people with Type 2 diabetes: Knowledge-based diabetes-specific guidelines2003
Emeritus Professor Philip Home
Issues relating to the early or earlier use of insulin in type 2 diabetes2003
Emeritus Professor Philip Home
It's all kidneys2003
Emeritus Professor Philip Home
PPAR- modulators: their role in diabetes care2003
Emeritus Professor Philip Home
Prevention comes of age2003
Emeritus Professor Philip Home
The challenge of poorly controlled diabetes mellitus2003
Emeritus Professor Philip Home
The very centre of care2003
Emeritus Professor Philip Home
Where next for IDF?2003
Emeritus Professor Philip Home
A randomized, multicentre trial of insulin glargine versus NPH insulin in people with Type 1 diabetes2002
Emeritus Professor Philip Home
Dr Simon Ashwell
An overview of insulin glargine2002
Emeritus Professor Philip Home
Clinical Guidelines and Evidence Review for Type 2 Diabetes2002
Emeritus Professor Philip Home
Rebecca Crow
Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose2002
Emeritus Professor Philip Home
Considerations on blood glucose management in type 2 diabetes mellitus2002
Emeritus Professor Philip Home
Expensive new drugs: NICE , or not so nice?2002
Emeritus Professor Philip Home
Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes2002
Emeritus Professor Philip Home
Organisation of Diabetes Care2002
Emeritus Professor Philip Home
Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: A randomized trial in Type 1 and Type 2 diabetic patients2002
Emerita Professor Sally Marshall
Emeritus Professor Philip Home
Standardization of glycated haemoglobin [1]2002
Emerita Professor Sally Marshall
Emeritus Professor Philip Home
Standardization of glycated haemoglobin [2]2002
Emeritus Professor Philip Home
The drug dilemma2002
Dr Alison Gallagher
Emeritus Professor Philip Home
The effect of insulin aspart on post-prandial metabolism and lipid profile in Type 2 diabetes2002
Emeritus Professor Philip Home
The interaction between frequency of hypoglycaemia, single and multiplevascular complications and health utility2002
Emeritus Professor Philip Home
Therapeutic targets in the management of type 1 diabetes2002
Emeritus Professor Philip Home
Thiazolidenediones: increasing insulin sensitivity2002
Emeritus Professor Philip Home
Biphasic insulin aspart and biphasic human insulin compared in Type 2 diabetic subjects2001
Emeritus Professor Philip Home
Gestational impaired glucose tolerance does not increase perinatal mortality in a developing country: cohort study2001
Emeritus Professor Philip Home
Insulin aspart safe for long-term treatment2001
Dr Simon Ashwell
Emeritus Professor Philip Home
Insulin glargine: The first clinically useful extended-action insulin analogue2001
Dr Alison Gallagher
Emeritus Professor Philip Home
The effect of insulin aspart on postprandial metabolism and metabolic outcome in Type 2 diabetes2001
Emeritus Professor Philip Home
Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial2000
Emeritus Professor Philip Home
Insulin glargine - Viewpoint2000
Emeritus Professor Philip Home
Postprandial hyperglycaemia: Mechanisms and importance2000
Emeritus Professor Philip Home
Rapid-acting insulin analogues: When randomized clinical trial results do not help2000
Emeritus Professor Sir George Sir George Alberti
Professor Rudy Bilous
Emeritus Professor Philip Home
Torgrim Lauritsen
A desktop guide to Type 1 (insulin-dependent) diabetes mellitus1999
Emeritus Professor Sir George Sir George Alberti
Professor Rudy Bilous
Emeritus Professor Philip Home
Torgrim Lauritsen
A desktop guide to Type 2 diabetes mellitus1999
Emeritus Professor Philip Home
Dr Luis Barriocanal
Comparative pharmacokinetics and pharmacodynamics of the novel rapid- acting insulin analogue, insulin aspart, in healthy volunteers1999
Emeritus Professor Philip Home
Insulin aspart1999
Emeritus Professor Philip Home
Insulin aspart improves long-term glycaemic control in Type 1 diabetes - A randomized trial vs. human insulin1999
Emeritus Professor Philip Home
Insulin glargine: The first clinically useful extended-acting insulin in half a century?1999
Emeritus Professor Philip Home
Rapid-acting insulin secretagogues: a clinical need?1999
Emeritus Professor Philip Home
Rapid-acting insulin secretagogues: a clinical need?1999
Emeritus Professor Philip Home
Untitled - Foreword1999